ADAM10 is Involved in the Oncogenic Process and Chemo-resistance of Triple-negative Breast Cancer Via Regulating Notch1 Signaling Pathway, CD44 and PrPc

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2021 Jan 8

PMID 33413403

Citations 18

Authors

Yuanyuan Cheng

Lishuang Lin

Xiaoyan Li

Aiqi Lu

Chenjian Hou

Qian Wu

Xiaomu Hu

Zhongwen Zhou

Zhongqing Chen

Feng Tang

Affiliations

Soon will be listed here.

Abstract

Background: Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype to treat, because it is so aggressive with shorter survival. Chemotherapy remains the standard treatment due to the lack of specific and effective molecular targets. The aim of the present study is to investigate the potential roles of A Disintegrin and Metalloproteinase 10 (ADAM10) on TNBC cells and the effects of combining ADAM10 expression and neoadjuvant chemotherapy treatment (NACT) to improve the overall survival in breast cancer patients.

Methods: Using a series of breast cancer cell lines, we measured the expression of ADAM10 and its substrates by quantitative real-time PCR assay (qRT-PCR) and western blot analysis. Cell migration and invasion, cell proliferation, drug sensitivity assay, cell cycle and apoptosis were conducted in MDA-MB-231 cells cultured with ADAM10 siRNA. The effect of ADAM10 down-regulation by siRNA on its substrates was assessed by western blot analysis. We performed immunohistochemical staining for ADAM10 in clinical breast cancer tissues in 94 patients receiving NACT.

Results: The active form of ADAM10 was highly expressed in TNBC cell lines. Knockdown of ADAM10 in MDA-MB-231 cells led to a significant decrease in cell proliferation, migration, invasion and the IC value of paclitaxel and adriamycin, while induced cell cycle arrest and apoptosis. And these changes were correlated with down-regulation of Notch signaling, CD44 and cellular prion protein (PrPc). In clinical breast cancer cases, a high ADAM10 expression in pre-NACT samples was strongly associated with poorer response to NACT and shorter overall survival.

Conclusions: These data suggest the previously unrecognized roles of ADAM10 in contributing to the progression and chemo-resistance of TNBC.

Citing Articles

Prodelphinidin B-2,3,3"-O-gallate via chemical oxidation of epigallocatechin-3-gallate shows high efficacy inhibiting triple-negative breast cancer cells.

Wang J, Wang Y, Zhang S, Hu H, Zhang R, Zi C BMC Pharmacol Toxicol. 2025; 26(1):48.

PMID: 40022263 PMC: 11869402. DOI: 10.1186/s40360-025-00883-6.

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Serrano Garcia L, Javega B, Llombart Cussac A, Gion M, Perez-Garcia J, Cortes J Front Immunol. 2024; 15:1513421.

PMID: 39735530 PMC: 11671371. DOI: 10.3389/fimmu.2024.1513421.

Circ_0096710 facilitates tumor growth via controlling ADAM10 expression in esophageal squamous cell carcinoma.

Dong C, Li Z Thorac Cancer. 2024; 16(1):e15483.

PMID: 39620490 PMC: 11729450. DOI: 10.1111/1759-7714.15483.

Targeting the NOTCH2/ADAM10/TCF7L2 Axis-Mediated Transcriptional Regulation of Wnt Pathway Suppresses Tumor Growth and Enhances Chemosensitivity in Colorectal Cancer.

Xiang Z, Wang Y, Ma X, Song S, He Y, Zhou J Adv Sci (Weinh). 2024; 12(3):e2405758.

PMID: 39601111 PMC: 11744699. DOI: 10.1002/advs.202405758.

Dual Roles of microRNA-122 in Hepatocellular Carcinoma and Breast Cancer Progression and Metastasis: A Comprehensive Review.

Al Ageeli E Curr Issues Mol Biol. 2024; 46(11):11975-11992.

PMID: 39590305 PMC: 11592835. DOI: 10.3390/cimb46110711.

References

Ogston K, Miller I, Payne S, Hutcheon A, Sarkar T, Smith I . A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003; 12(5):320-7. DOI: 10.1016/s0960-9776(03)00106-1. View

Inoshima I, Inoshima N, Wilke G, Powers M, Frank K, Wang Y . A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med. 2011; 17(10):1310-4. PMC: 3192248. DOI: 10.1038/nm.2451. View

Li Q, Cao X, Xu J, Chen Q, Wang W, Tang F . The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel. Cell Mol Life Sci. 2008; 66(3):504-15. PMC: 11131458. DOI: 10.1007/s00018-008-8548-6. View

Hartmann M, Parra L, Ruschel A, Lindner C, Morrison H, Herrlich A . Inside-out Regulation of Ectodomain Cleavage of Cluster-of-Differentiation-44 (CD44) and of Neuregulin-1 Requires Substrate Dimerization. J Biol Chem. 2015; 290(28):17041-54. PMC: 4498042. DOI: 10.1074/jbc.M114.610204. View

Hartmann D, De Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W . The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet. 2002; 11(21):2615-24. DOI: 10.1093/hmg/11.21.2615. View

Mullooly M, McGowan P, Kennedy S, Madden S, Crown J, Donovan N . ADAM10: a new player in breast cancer progression?. Br J Cancer. 2015; 113(6):945-51. PMC: 4578086. DOI: 10.1038/bjc.2015.288. View

Armanious H, Gelebart P, Anand M, Belch A, Lai R . Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway. Blood. 2011; 117(23):6237-46. DOI: 10.1182/blood-2010-10-313940. View

Takebe N, Harris P, Warren R, Ivy S . Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2010; 8(2):97-106. DOI: 10.1038/nrclinonc.2010.196. View

Idowu M, Kmieciak M, Dumur C, Burton R, Grimes M, Powers C . CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol. 2011; 43(3):364-73. DOI: 10.1016/j.humpath.2011.05.005. View

10.

Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready D . High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005; 65(18):8530-7. DOI: 10.1158/0008-5472.CAN-05-1069. View

11.

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

12.

Wetzel S, Seipold L, Saftig P . The metalloproteinase ADAM10: A useful therapeutic target?. Biochim Biophys Acta Mol Cell Res. 2017; 1864(11 Pt B):2071-2081. DOI: 10.1016/j.bbamcr.2017.06.005. View

13.

Borggrefe T, Oswald F . The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci. 2009; 66(10):1631-46. PMC: 11115614. DOI: 10.1007/s00018-009-8668-7. View

14.

Goulding H, Pinder S, Cannon P, Pearson D, Nicholson R, Snead D . A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol. 1995; 26(3):291-4. DOI: 10.1016/0046-8177(95)90060-8. View

15.

Ji X, Lu Y, Tian H, Meng X, Wei M, Cho W . Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019; 114:108800. DOI: 10.1016/j.biopha.2019.108800. View

16.

Niimi H, Pardali K, Vanlandewijck M, Heldin C, Moustakas A . Notch signaling is necessary for epithelial growth arrest by TGF-beta. J Cell Biol. 2007; 176(5):695-707. PMC: 2064026. DOI: 10.1083/jcb.200612129. View

17.

Seals D, Courtneidge S . The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003; 17(1):7-30. DOI: 10.1101/gad.1039703. View

18.

Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E . A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 2004; 113(10):1456-64. PMC: 406531. DOI: 10.1172/JCI20864. View

19.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

20.

Knosel T, Emde A, Schluns K, Chen Y, Jurchott K, Krause M . Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia. 2005; 7(8):741-7. PMC: 1501883. DOI: 10.1593/neo.05178. View